Sequential treatment in disseminated well- and intermediate-differentiated pancreatic neuroendocrine tumors: Common sense or low rationale?

Figure 1 Summary of the mode of actions of the different available alternatives for the systemic management of pancreatic neuroendocrine tumor patients. PNET: Pancreatic neuroendocrine tumor; VEGF: Vascular endothelial growth factor; PI3K: Phosphatidylinositol 3-kinase; mTOR: Mammalian target of rapamycin.

Figure 2 Different sequential alternatives to be used in advanced pancreatic neuroendocrine tumor patients based on approved agents. The term “chemotherapy” may include streptozocin ± 5-fluorouracil or doxorubicin, or temozolomide ± capecitabine.